Abacus Global Management (ABX): Assessing the Path to $15
Key Takeaways
- Abacus Global Management, Inc. (ABX) recently traded in the high single digits, with a 52-week range of roughly $5.00 to $12.44, leaving the $15 target well above its prior peak.
- The strongest bullish case rests on accelerating life-settlement origination, a new $100 million buyback authorization, and analyst price targets that extend as high as $15 to $16.
- The biggest obstacles are margin compression, inconsistent quarterly earnings, insider selling, and the fact that $15 sits above even the stock's all-time trading high.
- Key technical markers include the $12.44 52-week high as the primary resistance level and the $9 to $10 zone as near-term support.
- Reaching $15 would likely require durable earnings growth, successful monetization of its longevity platform, and a broader re-rating by investors.
Why the $15 Level Stands Out
The central question surrounding ABX is whether the stock can reclaim momentum and push toward $15, a level cited by multiple analysts and one that would mark a decisive breakout above the company's 52-week high of $12.44. For a company that has spent much of the past year trading between $5 and the low teens, $15 represents a meaningful psychological milestone as well as a technical one. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Overview
Abacus Global Management, Inc. is a U.S.-listed stock — not an ETF — operating as an alternative asset manager specializing in life insurance policy monetization. The company, formerly known as Abacus Life, buys life insurance policies from consumers seeking liquidity and manages those policies over time, while also building out asset management, wealth management, and data-driven technology services through its LifeARC platform. Its segments include life solutions, asset management, and technology services.
Current Market Position
The company recently reported second-quarter revenue of about $73 million, up roughly 30% year over year, driven by a 38% increase in its core life solutions business. Adjusted net income came in at approximately $27 million, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) near $40 million. For the full year, management reiterated adjusted net income guidance of $100 million to $106 million and adjusted earnings per share (EPS) of $1.00 to $1.05.
Factors That Could Support a Move Higher
Several factors support a move toward $15. First, the company's origination engine is accelerating, with roughly $362 million in capital deployed in the first half of the year and strong inflows into its longevity funds. Second, a newly authorized $100 million share buyback, representing up to about 12% of outstanding shares, signals that management views the stock as undervalued. Third, the company's expanding technology fee revenue and its Manning & Napier distribution partnership offer potential pathways to more durable, higher-margin earnings.
Challenges on the Road to $15
The path to $15 is far from assured. Despite strong top-line growth, reported net income declined sharply in the most recent quarter, falling to roughly $6.6 million from about $17.6 million a year earlier, reflecting rising operating expenses tied to acquisitions and platform build-out. Major shareholders also sold shares over the past three months, which can weigh on sentiment. Most importantly, $15 is a level the stock has never sustained, meaning it would require not just operational execution but a genuine re-rating in valuation.
Analyst Views and Price Targets
Analyst coverage is broadly constructive but divided. The consensus rating sits near "Moderate Buy," with average 12-month price targets clustering in the $12 to $14 range. Piper Sandler maintains a neutral stance, trimming its target from $13 to $12, while Texas Capital initiated coverage with a "strong buy" and a $15 target, and B. Riley has pointed toward $16. Maxim Group has also cited $15. In this context, the $15 level functions as the upper bound of mainstream analyst expectations rather than a consensus forecast.
Key Technical Levels
From a technical analysis perspective, the $12.44 52-week high is the critical resistance level — a sustained close above it would confirm a breakout and open the door toward $15. On the downside, the $9 to $10 area, which aligns with the stock's 50-day moving average and its recent trading range, acts as near-term support. The $10 round number is also a widely watched psychological level for traders. One thing that stands out when reviewing the charts is how the stock has behaved around these zones.
Final Assessment
Whether ABX can realistically reach $15 depends on a combination of execution and sentiment. The bullish case is credible: accelerating origination, a sizable buyback, and high-end analyst targets all point in that direction. Yet the obstacles are equally real, including margin pressure, inconsistent profitability, insider selling, and the fact that $15 would require the stock to trade above its all-time high. Investors monitoring the position should watch revenue quality, adjusted earnings trends, buyback activity, and whether the stock can first clear the $12.44 resistance level before entertaining the $15 scenario.
Exploring Tickeron’s AI Daily Buy/Sell Signals
I often rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of market shifts for stocks like ABX. The tool uses artificial intelligence to scan thousands of securities and deliver timely Buy, Sell, or Hold signals based on technical patterns and broader conditions, helping me cross-check ideas without replacing my own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABX in -4.78% downward trend, sliding for three consecutive days on September 18, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABX declined for three days, in 153 of 200 cases, the price declined further within the following month. The odds of a continued downward trend are 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABX as a result. In 63 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for ABX turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 31 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
The 10-day moving average for ABX crossed bearishly below the 50-day moving average on August 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for ABX entered a downward trend on August 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ABX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABX advanced for three days, in 144 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ABX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. ABX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.973) is normal, around the industry mean (1.398). P/E Ratio (32.481) is within average values for comparable stocks, (20.801). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (0.468). Dividend Yield (0.023) settles around the average of (0.037) among similar stocks. ABX's P/S Ratio (3.453) is very high in comparison to the industry average of (1.303).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a mines and an explorer for gold
Industry LifeHealthInsurance
Advertisement